Castle BiosciencesCSTL +1.13%72 Beneish M-Score is -3.04 as of Jun. 25, 2026. GuruFocus rates CSTL with a GF Score™ of 72/100 and a GF Value™ of $29.15 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 195 Medical Diagnostics & Research companies, Castle Biosciences ranks better than 74.87% on this metric.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Good Sign:
Beneish M-Score -3.04 no higher than -1.78, which implies that the company is unlikely to be a manipulator.
The historical rank and industry rank for Castle Biosciences's Beneish M-Score or its related term are showing as below:
CSTL'
s Beneish M-Score Range Over the Past 10 Years
Min: -3.51 Med: -2.5 Max: 10.51
Current: -3.04
During the past 9 years, the highest Beneish M-Score of Castle Biosciences was 10.51. The lowest was -3.51. And the median was -2.50.
Castle Biosciences Beneish M-Score Related Terms
Castle Biosciences Beneish M-Score Historical Data
* Premium members only.
The historical data trend for Castle Biosciences's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSTL vs FLGT, MYGN, PRE: Beneish M-Score Comparison
For the Diagnostics & Research subindustry, Castle Biosciences's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Castle Biosciences Beneish M-Score vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Castle Biosciences's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where Castle Biosciences's Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of Castle Biosciences for today is based on a combination of the following eight different indices:
M
=
-4.84
+
0.92 * DSRI
+
0.528 * GMI
+
0.404 * AQI
+
0.892 * SGI
+
0.115 * DEPI
=
-4.84
+
0.92 * 0.7658
+
0.528 * 1.052
+
0.404 * 1.1061
+
0.892 * 0.9794
+
0.115 * 3.3948
-
0.172 * SGAI
+
4.679 * TATA
-
0.327 * LVGI
-
0.172 * 1.1446
+
4.679 * -0.11994
-
0.327 * 1.2484
=
-3.04
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI
=
(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))
/
(Depreciation_t / (Depreciaton_t + PPE_t))
=
(42.421 / (42.421 + 66.587))
/
(14.936 / (14.936 + 115.358))
=
0.389155
/
0.114633
=
3.3948
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA
=
(IncomefromContinuingOperations_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(NetIncome_t - NonOperatingIncome_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(-12.832 - 4.618
-
48.254)
/
547.805
=
-0.11994
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Castle Biosciences has a M-score of -3.04 suggests that the company is unlikely to be a manipulator.
Castle Biosciences (CSTL) has a Beneish M-Score of -3.04 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Castle Biosciences and its competitors. According to the industry distribution chart, Castle Biosciences ranks #49 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 25.1%.
Is Castle Biosciences' Beneish M-Score too high?
Castle Biosciences' current Beneish M-Score is -3.04. Based on the distribution chart, Castle Biosciences ranks #49 out of 195 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Castle Biosciences has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Castle Biosciences' Beneish M-Score compare to FLGT and MYGN?
According to the Medical Diagnostics & Research industry distribution chart, Castle Biosciences ranks #49 out of 195 companies for Beneish M-Score. This puts Castle Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Diagnostics & Research company?
A good Beneish M-Score depends on the Medical Diagnostics & Research industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Castle Biosciences and its competitors. Castle Biosciences's current Beneish M-Score is -3.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Castle Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Castle Biosciences (CSTL) is currently considered Modestly Undervalued. The stock's GF Value™ is $29.15, compared to a current price of $22.37 — trading 23.3% below its estimated fair value. The current Beneish M-Score is -3.04. Castle Biosciences' overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Castle Biosciences (CSTL), the current Beneish M-Score is -3.04 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Castle Biosciences (CSTL) Overvalued in 2026?
Based on GuruFocus' analysis, Castle Biosciences stock appears to be undervalued.
The current stock price of $22.37 is trading 23.3% below its estimated GF Value™ of $29.15.
GuruFocus considers Castle Biosciences to be Modestly Undervalued.
Key valuation signals for CSTL:
Beneish M-Score: -3.04
GF Value™: $29.15 vs. price of $22.37 (23.3% below fair value)
No single metric tells the full story. See the CSTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
72GF Score
Get the complete analysis for CSTL
Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSTL has been successfully added to your 
